Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Aquestive Therapeutics, Inc. has received a consensus rating of "Moderate Buy" from eight brokerages, with an average 12-month target price of $10.14.
• Institutional investors have been active, with Wells Fargo increasing its holdings by 54.3% and Renaissance Technologies boosting its stake by 233.6% in the fourth quarter.
• The company reported a better-than-expected earnings result of ($0.14) EPS, beating the consensus estimate and generating $10 million in revenue for the quarter, although this was below analyst expectations.

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eight brokerages that are covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $10.1429.

A number of research firms recently issued reports on AQST. Zacks Research raised Aquestive Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 13th. Oppenheimer initiated coverage on Aquestive Therapeutics in a research note on Monday, June 2nd. They issued an "outperform" rating and a $7.00 price objective on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research note on Tuesday, June 17th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of AQST. Pale Fire Capital SE boosted its position in Aquestive Therapeutics by 154.1% in the 1st quarter. Pale Fire Capital SE now owns 1,335,684 shares of the company's stock valued at $3,873,000 after buying an additional 809,928 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Aquestive Therapeutics by 905.2% in the 4th quarter. Bank of America Corp DE now owns 690,284 shares of the company's stock valued at $2,457,000 after purchasing an additional 621,614 shares during the period. Sio Capital Management LLC raised its stake in shares of Aquestive Therapeutics by 141.9% in the 2nd quarter. Sio Capital Management LLC now owns 947,489 shares of the company's stock valued at $3,136,000 after purchasing an additional 555,860 shares during the period. Everstar Asset Management LLC increased its position in shares of Aquestive Therapeutics by 119.5% in the second quarter. Everstar Asset Management LLC now owns 658,607 shares of the company's stock valued at $2,180,000 after acquiring an additional 358,607 shares during the last quarter. Finally, Stifel Financial Corp increased its position in shares of Aquestive Therapeutics by 315.4% in the fourth quarter. Stifel Financial Corp now owns 398,561 shares of the company's stock valued at $1,419,000 after acquiring an additional 302,617 shares during the last quarter. 32.45% of the stock is currently owned by institutional investors.

Aquestive Therapeutics Trading Down 1.6%

NASDAQ AQST traded down $0.06 during mid-day trading on Thursday, reaching $3.77. 1,032,623 shares of the company's stock traded hands, compared to its average volume of 1,480,118. The company has a fifty day simple moving average of $3.86 and a 200-day simple moving average of $3.20. Aquestive Therapeutics has a 1-year low of $2.12 and a 1-year high of $5.80. The company has a market cap of $375.94 million, a price-to-earnings ratio of -5.39 and a beta of 1.82.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.04. The company had revenue of $10.00 million during the quarter, compared to the consensus estimate of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. Equities research analysts forecast that Aquestive Therapeutics will post -0.46 earnings per share for the current fiscal year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.